Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Show more

Location: 259 Liberty Avenue, Staten Island, NY, 10305, United States | Website: https://www.acurxpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

6.569M

52 Wk Range

$3.80 - $44.00

Previous Close

$4.14

Open

$3.96

Volume

50,814

Day Range

$3.83 - $4.15

Enterprise Value

504.8K

Cash

6.064M

Avg Qtr Burn

-2.041M

Insider Ownership

8.12%

Institutional Own.

13.95%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.